{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:17:50Z","timestamp":1785842270095,"version":"3.56.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K07 CA166210"],"award-info":[{"award-number":["K07 CA166210"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K0720103"],"award-info":[{"award-number":["K0720103"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Janet Files for administrative and organizational assistance"},{"name":"Layla Rouse"},{"name":"Monir Corona"},{"name":"National Comprehensive Cancer Center"}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ajog.2019.06.009","type":"journal-article","created":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T11:02:24Z","timestamp":1560510144000},"page":"625.e1-625.e14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Outcomes of secondary cytoreductive surgery for\u00a0patients with platinum-sensitive recurrent ovarian\u00a0cancer"],"prefix":"10.1016","volume":"221","author":[{"given":"Allison","family":"Gockley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Melamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Cronin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Bookman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela C.","family":"Cristae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Griggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Mantia-Smaldone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula A.","family":"Matulonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2687-7463","authenticated-orcid":false,"given":"Larissa A.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Niland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"O\u2019Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexi A.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2019.06.009_bib1","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2019.06.009_bib2","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","article-title":"Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial","volume":"13","author":"Harter","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ajog.2019.06.009_bib3","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/bjc.2011.328","article-title":"Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort","volume":"105","author":"Zang","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajog.2019.06.009_bib4","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<144::AID-CNCR20>3.0.CO;2-X","article-title":"The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma","volume":"88","author":"Eisenkop","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ajog.2019.06.009_bib5","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1006\/gyno.2001.6404","article-title":"Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma","volume":"83","author":"Scarabelli","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2019.06.009_bib6","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.21845","article-title":"Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma","volume":"106","author":"Chi","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ajog.2019.06.009_bib7","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/annonc\/mdn591","article-title":"The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer","volume":"20","author":"Oksefjell","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ajog.2019.06.009_bib8","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/jso.21491","article-title":"Surgery in recurrent epithelial ovarian cancer: benefits on survival for patients with residual disease of 0.1-1 cm after secondary cytoreduction","volume":"101","author":"Tian","year":"2010","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.ajog.2019.06.009_bib9","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/jso.21652","article-title":"Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients","volume":"102","author":"Sehouli","year":"2010","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.ajog.2019.06.009_bib10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ygyno.2013.06.020","article-title":"Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors","volume":"131","author":"Petrillo","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2019.06.009_bib11","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ygyno.2016.01.027","article-title":"Performance of AGO score for secondary cytoreduction in a high-volume U.S. center","volume":"141","author":"Janco","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2019.06.009_bib12","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.2004.05.195","article-title":"Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design","volume":"22","author":"Markman","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2019.06.009_bib13","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.2165\/11591720-000000000-00000","article-title":"Management strategies for recurrent platinum-resistant ovarian cancer","volume":"71","author":"Naumann","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.ajog.2019.06.009_bib14","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2019.06.009_bib15","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy vs conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ajog.2019.06.009_bib16","first-page":"426","article-title":"Management of newly diagnosed or recurrent ovarian cancer","volume":"16","author":"Matulonis","year":"2018","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.ajog.2019.06.009_bib17","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1200\/JCO.2017.35.15_suppl.5501","article-title":"Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III\/ENGOT ov20","volume":"35","author":"Bois","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2019.06.009_bib18","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1200\/JCO.2018.36.15_suppl.5501","volume":"36","author":"Coleman","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2019.06.009_bib19","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/IGC.0000000000000841","article-title":"Correspondence: Premature stop of the SOCceR trial, a multicenter randomized\u00a0controlled trial on secondary cytoreductive surgery Netherlands Trial Register Number NTR3337","volume":"27","author":"van de Laar","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ajog.2019.06.009_bib20","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/IGC.0b013e31820aaafd","article-title":"Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO","volume":"21","author":"Harter","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ajog.2019.06.009_bib21","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1002\/cncr.23911","article-title":"Reliability of staging, prognosis, and comorbidity data collection in the National Comprehensive Cancer Network (NCCN) non-Hodgkin lymphoma (NHL) multicenter outcomes database","volume":"113","author":"Kho","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ajog.2019.06.009_bib22","doi-asserted-by":"crossref","first-page":"20","DOI":"10.7326\/M13-2231","article-title":"Interinstitutional variation in management decisions for treatment of 4 common types of cancer: a multi-institutional cohort study","volume":"161","author":"Weeks","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ajog.2019.06.009_bib23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A\u00a0new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J\u00a0Chronic Dis"},{"key":"10.1016\/j.ajog.2019.06.009_bib24","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ajog.2019.06.009_bib25","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1097\/EDE.0000000000000733","article-title":"On a square-root transformation of the odds ratio for a common outcome","volume":"28","author":"VanderWeele","year":"2017","journal-title":"Epidemiology"},{"key":"10.1016\/j.ajog.2019.06.009_bib26","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","article-title":"Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial","volume":"13","author":"Harter","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ajog.2019.06.009_bib27","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/cncr.20106","article-title":"Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?","volume":"100","author":"Zang","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ajog.2019.06.009_bib28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1006\/gyno.1998.4955","article-title":"Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study","volume":"69","author":"Eisenkop","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2019.06.009_bib29","first-page":"CD008765","article-title":"Surgical cytoreduction for recurrent epithelial ovarian cancer","author":"Al Rawahi","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ajog.2019.06.009_bib30","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ygyno.2008.08.033","article-title":"Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis","volume":"112","author":"Bristow","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2019.06.009_bib31","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejogrb.2018.06.036","article-title":"Secondary cytoreductive surgery\u2014viable treatment option in the management of platinum-sensitive recurrent ovarian cancer","volume":"228","author":"Felsinger","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ajog.2019.06.009_bib32","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/cncr.22447","article-title":"Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome","volume":"109","author":"Salani","year":"2007","journal-title":"Cancer"},{"issue":"Suppl 10","key":"10.1016\/j.ajog.2019.06.009_bib33","first-page":"235","article-title":"The role of surgery in advanced and recurrent ovarian cancer","volume":"17","author":"du Bois","year":"2006","journal-title":"Ann Oncol"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937819307732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937819307732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:28:54Z","timestamp":1757590134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937819307732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0002937819307732"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2019.06.009","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of secondary cytoreductive surgery for\u00a0patients with platinum-sensitive recurrent ovarian\u00a0cancer","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2019.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}